A clinical-stage biopharmaceutical company announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801.
Altimmune, Inc. stated in a press release that ‘ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the USA.’
Read More
